M Bialer
Overview
Explore the profile of M Bialer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tonelli A, Bialer M, Look Z, Carson S, Yacobi A
Pharm Res
. 2013 Nov;
3(3):150-5.
PMID: 24271520
The pharmacokinetics of cefixime, a new orally active cephalosporin, was studied after an intravenous dose of 50 mg/kg to four beagle dogs. Cefixime was shown to exhibit concentration dependent serum...
2.
Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, et al.
Neuroscience
. 2012 Nov;
231:145-56.
PMID: 23159312
Better treatment of status epilepticus (SE), which typically becomes refractory after about 30 min, will require new pharmacotherapies. The effect of sec-butyl-propylacetamide (SPD), an amide derivative of valproic acid (VPA),...
3.
Shimshoni J, Dalton E, Jenkins A, Eyal S, Ewan K, Williams R, et al.
Mol Pharmacol
. 2006 Dec;
71(3):884-92.
PMID: 17167030
Valproic acid (VPA) is an effective antiepileptic drug with an additional activity for the treatment of bipolar disorder. It has been assumed that both activities arise from a common target....
4.
Mannens G, Hendrickx J, Janssen C, Chien S, Van Hoof B, Verhaeghe T, et al.
Drug Metab Dispos
. 2006 Aug;
35(4):554-65.
PMID: 16936066
RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-; CAS Registry Number 194085-75-1) is a novel neuromodulator in clinical development for the treatment of epilepsy. To study the disposition of RWJ-333369, eight healthy male...
5.
Eyal S, Lamb J, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al.
Br J Pharmacol
. 2006 Aug;
149(3):250-60.
PMID: 16894351
Background And Purpose: The antiepileptic drug valproic acid, a histone deacetylase (HDAC) inhibitor, is currently being tested as an anticancer agent. However, HDAC inhibitors may interact with anticancer drugs through...
6.
Bialer M
Zh Nevrol Psikhiatr Im S S Korsakova
. 2005 Oct;
105(9):59-60.
PMID: 16250582
No abstract available.
7.
Bialer M, Johannessen S, KUPFERBERG H, Levy R, Loiseau P, Perucca E
Epilepsy Res
. 2002 Sep;
51(1-2):31-71.
PMID: 12350382
The Sixth Eilat Conference on New Antiepileptic Drugs (AEDs) took place in Taormina, Sicily, Italy from 7th to 11th April, 2002. Basic scientists, clinical pharmacologists and neurologists from 27 countries...
8.
Isoherranen N, Woodhead J, White H, Bialer M
Epilepsia
. 2001 Aug;
42(7):831-6.
PMID: 11488880
Purpose: We sought to investigate the anticonvulsant activity of the new antiepileptic drug (AED), valrocemide or TV1901 (VGD) in various animal (rodent) models of human epilepsy to determine its anticonvulsant...
9.
Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M
Epilepsia
. 2001 Aug;
42(7):825-30.
PMID: 11488879
Purpose: The new antiepileptic drug, levetiracetam (LEV, ucb LO59), is a chiral molecule with one asymmetric carbon atom whose anticonvulsant activity is highly enantioselective. The purpose of this study was...
10.
Wasserman M, Yagen B, Blotnik S, Papo N, Bialer M
Ther Drug Monit
. 2001 Jul;
23(4):414-20.
PMID: 11477326
The purpose of this study was to evaluate the anticonvulsant activity and pharmacokinetics (PK) of a novel chiral CNS-active 2-hydroxypropyl valpromide (HP-VPD), a derivative of valproic acid (VPA). The individual...